Germany 16.5%, UK 13.4%, France 13.1% of European market Middle East & Africa: 16.26% CAGR Saudi Arabia highest T2D prevalence globally at 24% (IDF 2024)
Finally, different weight loss medications raised concerns about suicidality in the past, including phentermine/topiramate, bupropion/naltrexone, and especially rimonabant, an inverse agonist for the cannabinoid receptor CB1, which was worldwide withdrawn for increased risk of suicidality.SGLT2 inhibitors for depression are a relatively new topic
Description GLP-1/GIP/GLUCAGON 10mg Research-Grade Peptide for GLP-1, GIP & Glucagon Receptor and Metabolic Pathway Studies Delivery: Laboratory Research-Grade, 10mg Vial, 99.89% GLP-1/GIP/GLUCAGON 10mg is a synthetic, research-grade peptide designed for laboratory investigations into GLP-1, GIP, and glucagon receptor signaling, metabolic pathways, and peptidereceptor biology
The findings provide a powerful counterpoint to the challenge of low medication adherence in real-world settings, where many patients stop taking GLP-1s before they can see the full clinical benefit
